Pharmacotherapeutic Options for Managing Neuropathic Pain: A Systematic Review and Meta-Analysis
Despite an increasing number of available therapies, the treatment of neuropathic pain remains a major issue. Systematic reviews and meta-analyses indicate that only a minority of patients with neuropathic pain have an adequate response to pharmacological treatment and that most drugs have dose-limi...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Pain Research and Management |
| Online Access: | http://dx.doi.org/10.1155/2021/6656863 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832565922480521216 |
|---|---|
| author | Giulia Di Stefano Andrea Di Lionardo Giuseppe Di Pietro Giorgio Cruccu Andrea Truini |
| author_facet | Giulia Di Stefano Andrea Di Lionardo Giuseppe Di Pietro Giorgio Cruccu Andrea Truini |
| author_sort | Giulia Di Stefano |
| collection | DOAJ |
| description | Despite an increasing number of available therapies, the treatment of neuropathic pain remains a major issue. Systematic reviews and meta-analyses indicate that only a minority of patients with neuropathic pain have an adequate response to pharmacological treatment and that most drugs have dose-limiting side effects. We conducted a systematic review and meta-analysis of randomised controlled trials published in the last five years. We searched for relevant papers within PubMed, EMBASE, the Cochrane Database of Systematic Reviews, and the Clinical Trials database (ClinicalTrials.gov). Two authors independently selected studies for inclusion, data extraction, and bias assessment. We identified 39 randomised controlled trials and included 16 in the meta-analysis. Trial outcomes were generally modest even for first-line drugs such as tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, and gabapentinoids. Many drugs acting on new pain targets are currently under development. Clinical data are currently available for sodium channel isoform-specific antagonists, anti-nerve growth factor molecules, and fatty acid amide hydrolase inhibitors. |
| format | Article |
| id | doaj-art-4ffe92fe326e442b9b6c8abfa7efbda5 |
| institution | Kabale University |
| issn | 1203-6765 1918-1523 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Pain Research and Management |
| spelling | doaj-art-4ffe92fe326e442b9b6c8abfa7efbda52025-02-03T01:05:31ZengWileyPain Research and Management1203-67651918-15232021-01-01202110.1155/2021/66568636656863Pharmacotherapeutic Options for Managing Neuropathic Pain: A Systematic Review and Meta-AnalysisGiulia Di Stefano0Andrea Di Lionardo1Giuseppe Di Pietro2Giorgio Cruccu3Andrea Truini4Department of Human Neuroscience, Sapienza University of Rome, Rome, ItalyDepartment of Human Neuroscience, Sapienza University of Rome, Rome, ItalyDepartment of Human Neuroscience, Sapienza University of Rome, Rome, ItalyDepartment of Human Neuroscience, Sapienza University of Rome, Rome, ItalyDepartment of Human Neuroscience, Sapienza University of Rome, Rome, ItalyDespite an increasing number of available therapies, the treatment of neuropathic pain remains a major issue. Systematic reviews and meta-analyses indicate that only a minority of patients with neuropathic pain have an adequate response to pharmacological treatment and that most drugs have dose-limiting side effects. We conducted a systematic review and meta-analysis of randomised controlled trials published in the last five years. We searched for relevant papers within PubMed, EMBASE, the Cochrane Database of Systematic Reviews, and the Clinical Trials database (ClinicalTrials.gov). Two authors independently selected studies for inclusion, data extraction, and bias assessment. We identified 39 randomised controlled trials and included 16 in the meta-analysis. Trial outcomes were generally modest even for first-line drugs such as tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, and gabapentinoids. Many drugs acting on new pain targets are currently under development. Clinical data are currently available for sodium channel isoform-specific antagonists, anti-nerve growth factor molecules, and fatty acid amide hydrolase inhibitors.http://dx.doi.org/10.1155/2021/6656863 |
| spellingShingle | Giulia Di Stefano Andrea Di Lionardo Giuseppe Di Pietro Giorgio Cruccu Andrea Truini Pharmacotherapeutic Options for Managing Neuropathic Pain: A Systematic Review and Meta-Analysis Pain Research and Management |
| title | Pharmacotherapeutic Options for Managing Neuropathic Pain: A Systematic Review and Meta-Analysis |
| title_full | Pharmacotherapeutic Options for Managing Neuropathic Pain: A Systematic Review and Meta-Analysis |
| title_fullStr | Pharmacotherapeutic Options for Managing Neuropathic Pain: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | Pharmacotherapeutic Options for Managing Neuropathic Pain: A Systematic Review and Meta-Analysis |
| title_short | Pharmacotherapeutic Options for Managing Neuropathic Pain: A Systematic Review and Meta-Analysis |
| title_sort | pharmacotherapeutic options for managing neuropathic pain a systematic review and meta analysis |
| url | http://dx.doi.org/10.1155/2021/6656863 |
| work_keys_str_mv | AT giuliadistefano pharmacotherapeuticoptionsformanagingneuropathicpainasystematicreviewandmetaanalysis AT andreadilionardo pharmacotherapeuticoptionsformanagingneuropathicpainasystematicreviewandmetaanalysis AT giuseppedipietro pharmacotherapeuticoptionsformanagingneuropathicpainasystematicreviewandmetaanalysis AT giorgiocruccu pharmacotherapeuticoptionsformanagingneuropathicpainasystematicreviewandmetaanalysis AT andreatruini pharmacotherapeuticoptionsformanagingneuropathicpainasystematicreviewandmetaanalysis |